Skip to main content
. 2016 Jan 25;17(2):199–207. doi: 10.1080/15384047.2016.1139231

Figure 7.

Figure 7.

(A) Effect of EBI-907 on proliferation of colorectal cancer cell lines with innate resistance to Vemurafenib. (B) combination with EGFR inhibitor (SHR1258) enhanced the potency of BRAF inhibitor EBI-907 in inhibiting the proliferation of colorectal cancer cell lines. Data were expressed as mean ± SD (n = 3).